PA
XBI icon

Parallel Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Parallel Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.53M Buy
27,604
+317
+1% +$39.6K 0.06% 205
2025
Q4 		$3.33M Buy
27,287
+2,857
+12% +$328K 0.06% 209
2025
Q3 		$2.45M Sell
24,430
-699
-3% -$63K 0.04% 248
2025
Q2 		$2.08M Sell
25,129
-2,298
-8% -$183K 0.04% 266
2025
Q1 		$2.22M Sell
27,427
-15,147
-36% -$1.35M 0.05% 235
2024
Q4 		$3.83M Buy
42,574
+1,568
+4% +$152K 0.09% 176
2024
Q3 		$4.05M Sell
41,006
-24
-0.1% -$2.36K 0.1% 163
2024
Q2 		$3.8M Sell
41,030
-166
-0.4% -$14.9K 0.1% 159
2024
Q1 		$3.91M Sell
41,196
-787
-2% -$73K 0.11% 146
2023
Q4 		$3.75M Buy
41,983
+886
+2% +$65.8K 0.11% 144
2023
Q3 		$3M Buy
41,097
+195
+0.5% +$15.6K 0.1% 158
2023
Q2 		$3.4M Buy
40,902
+346
+0.9% +$28.9K 0.11% 149
2023
Q1 		$3.09M Buy
40,556
+31,435
+345% +$2.61M 0.1% 158
2022
Q4 		$757K Sell
9,121
-443
-5% -$35.9K 0.03% 310
2022
Q3 		$759K Sell
9,564
-370
-4% -$31.2K 0.03% 293
2022
Q2 		$738K Buy
9,934
+725
+8% +$54.4K 0.03% 296
2022
Q1 		$835K Sell
9,209
-26
-0.3% -$2.4K 0.03% 306
2021
Q4 		$1.03M Buy
9,235
+386
+4% +$46.6K 0.04% 266
2021
Q3 		$1.11M Sell
8,849
-139
-2% -$17.9K 0.04% 244
2021
Q2 		$1.22M Sell
8,988
-30
-0.3% -$3.94K 0.05% 223
2021
Q1 		$1.22M Sell
9,018
-12
-0.1% -$1.8K 0.06% 204
2020
Q4 		$1.27M Buy
9,030
+87
+1% +$11.1K 0.07% 184
2020
Q3 		$997K Sell
8,943
-513
-5% -$57.5K 0.06% 185
2020
Q2 		$1.06M Sell
9,456
-376
-4% -$37K 0.07% 171
2020
Q1 		$761K Sell
9,832
-548
-5% -$48.5K 0.06% 183
2019
Q4 		$987K Buy
10,380
+198
+2% +$17.1K 0.07% 183
2019
Q3 		$776K Buy
10,182
+116
+1% +$9.64K 0.07% 200
2019
Q2 		$883K Buy
10,066
+345
+4% +$29.4K 0.09% 171
2019
Q1 		$880K Sell
9,721
-150
-2% -$12.8K 0.1% 157
2018
Q4 		$708K Buy
9,871
+26
+0.3% +$2.1K 0.1% 150
2018
Q3 		$944K Buy
9,845
+395
+4% +$38.3K 0.12% 140
2018
Q2 		$899K Sell
9,450
-70
-0.7% -$6.43K 0.13% 126
2018
Q1 		$835K Buy
9,520
+235
+3% +$21.5K 0.13% 125
2017
Q4 		$788K Buy
9,285
+544
+6% +$45.6K 0.13% 123
2017
Q3 		$714K Buy
8,741
+200
+2% +$16K 0.12% 129
2017
Q2 		$668K Sell
8,541
-25
-0.3% -$1.77K 0.13% 130
2017
Q1 		$604K Buy
8,566
+1,266
+17% +$85K 0.12% 133
2016
Q4 		$432K Buy
+7,300
New +$451K 0.1% 148

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Parallel Advisors's XBI Position: Q1 2026 in Review

Parallel Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1.2% in Q1 2026, buying an estimated $39.6K and bringing the position to 27,604 shares worth $3.53M. The position accounts for 0.06% of the portfolio, ranked #205.

Parallel Advisors first reported a position in XBI in Q4 2016 and has held it in 38 quarters since. The position peaked at $4.05M in Q3 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Parallel Advisors held 27,604 shares of State Street SPDR S&P Biotech ETF worth $3.53M as of Q1 2026.
  • Parallel Advisors bought 317 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $39.6K.
  • State Street SPDR S&P Biotech ETF made up 0.06% of Parallel Advisors's portfolio in Q1 2026, its #205 holding.
  • Parallel Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 38 quarters since.
  • Parallel Advisors's State Street SPDR S&P Biotech ETF position peaked at $4.05M in Q3 2024.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.